

## **Product** Data Sheet

## L-Aspartic acid-<sup>13</sup>C<sub>4</sub>,<sup>15</sup>N

 Cat. No.:
 HY-N0666S1

 CAS No.:
 202468-27-7

 Molecular Formula:
 13C4H7, 15NO4

 Molecular Weight:
 138.07


Target: Endogenous Metabolite

Pathway: Metabolic Enzyme/Protease

**Storage:** 4°C, protect from light, stored under nitrogen

\* In solvent: -80°C, 6 months; -20°C, 1 month (protect from light, stored under

nitrogen)



## **BIOLOGICAL ACTIVITY**

Description	L-Aspartic acid- $^{13}$ C <sub>4</sub> , $^{15}$ N is the $^{13}$ C-labeled and $^{15}$ N-labeled L-Aspartic acid. L-Aspartic acid is is an amino acid, shown to be a suitable proagent for colon-specific agent deliverly.
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs <sup>[1]</sup> .  MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## **REFERENCES**

[1]. Hosoya K, et al. Blood-brain barrier produces significant efflux of L-aspartic acid but not D-aspartic acid: in vivo evidence using the brain efflux index method. J Neurochem. 1999 Sep;73(3):1206-11.

[2]. Leopold CS, et al. In vivo pharmacokinetic study for the assessment of poly(L-aspartic acid) as a drug carrier for colon-specific drug delivery. J Pharmacokinet Biopharm. 1995 Aug;23(4):397-406.

[3]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA